60岁以上手术治疗的WHO II级弥漫性胶质瘤的分子特征与临床结局
该研究回顾性分析了26例60岁以上、接受手术切除的WHO II级弥漫性胶质瘤患者,中位随访5.2年。IDH野生型弥漫性星形细胞瘤占26.9%,其中66%存在TERT突变;该亚型与更短的无进展生存期相关,但总生存期在各亚型间无差异。作者认为老年患者可安全接受积极手术及辅助治疗,但结局较年轻患者差。
要点
- 60岁以上WHO II级胶质瘤中IDH野生型星形细胞瘤占26.9%,66%伴TERT突变。
- IDH野生型星形细胞瘤亚型无进展生存期更短,总生存期各亚型无差异。
- 肿瘤体积较大及残留体积较大与恶性转化和死亡相关。
核心结论
- 老年弥漫性胶质瘤患者可安全接受手术切除联合辅助治疗的积极治疗。
- 老年低级别胶质瘤患者临床结局较年轻患者差,可能与IDH野生型弥漫性星形细胞瘤在该年龄组更常见有关。
研究设计与样本
- 经IRB批准后通过UCSF脑肿瘤中心识别患者,采用WHO 2016分级标准进行病理诊断。
- 纳入26例60岁以上、接受手术切除的WHO II级弥漫性胶质瘤患者,平均年龄66岁,中位随访5.2年。
主要发现
- 诊断构成:弥漫性星形细胞瘤IDH突变型19.2%,弥漫性星形细胞瘤IDH野生型26.9%,少突胶质细胞瘤IDH突变伴1p/19q共缺失50%,混合性少突星形细胞瘤3.9%。
- IDH野生型星形细胞瘤中66%存在TERT突变;中位切除程度为75.4%。
- 中位无进展生存期为23.5个月,中位总生存期为62.6个月。
- IDH野生型星形细胞瘤亚型与更短的无进展生存期相关,尽管其切除程度和辅助治疗率与其他亚型相似;总生存期在各亚型间无差异。
- 恶性转化和死亡与较大的术前肿瘤体积及残留肿瘤体积相关。
临床怎么用
- 作者认为,老年弥漫性胶质瘤患者可安全接受手术切除联合辅助治疗的积极治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: WHO grade II gliomas are uncommon in patients over the age of 60, and there is a lack in consensus regarding their management. We present molecular tumor characteristics as well as clinical outcomes in patients over the age of 60 undergoing surgical resection of a WHO grade II glioma. METHODS: After receiving IRB approval, patients were identified through the UCSF Brain Tumor Center. Pathologic diagnosis was completed using WHO 2016 grading criteria. RESULTS: Twenty-six patients with a mean age of 66 years met inclusion criteria with a median follow-up of 5.2 years. Diagnoses included diffuse astrocytoma IDH-mutant (19.2%), diffuse astrocytoma IDH-wildtype (26.9%), Oligodendroglioma IDH-mutant and 1p/19q-codeleted (50%), and a rare case of mixed oligoastrocytoma (3.9%). 66% of astrocytoma IDH-wildtype tumors possessed TERT mutation. Median extent of resection was 75.4%. Progression-free (PFS) and overall survival (OS) were 23.5 and 62.6 months, respectively. Shorter PFS was associated with the astrocytoma IDH-wildtype subtype despite similar extent of resection and adjuvant treatment rates compared to the other subtypes. OS did not differ between subtypes. Malignant transformation and death were associated with larger preoperative and residual tumor volume. CONCLUSIONS: Older patients with diffuse gliomas may safely undergo aggressive treatment with surgical resection and adjuvant therapy. Elderly patients with low grade gliomas have worse clinical outcomes compared to their younger counterparts. This may be due to an increased frequency of diffuse astrocytoma IDH-wildtype tumors in this age group.
引用
- Morshed RA, Han SJ, Hervey-Jumper SL, et al. Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60. J Neurooncol. 2018. PMID: 30498891. doi:10.1007/s11060-018-03044-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。